Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: A research study

BMC Pulmonary Medicine

Volumn 10, Issue , 2010, Pages

  Louhelainen, Noora ^a   Stark, Harri ^b   Mazur, Witold ^a   Rytilä, Paula ^a   Djukanovic, Ratko ^c   Kinnula, Vuokko L ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MATRILYSIN; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; MMP7 PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; NEUTROPHIL COUNT; PROSPECTIVE STUDY; SMOKING CESSATION; SMOKING HABIT; SPUTUM LEVEL; TREATMENT DURATION; AGED; ENZYMOLOGY; METABOLISM; MIDDLE AGED; NEUTROPHIL; SMOKING; SPUTUM;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHILS; PROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; SPUTUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77949446867     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-10-13     Document Type: Article

References (38)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.
2. Hogg JC, Chu F, Utokaprach S, Woods R, Elliot WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-53. 10.1056/NEJMoa032158, 15215480.
3. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994, 272(19):1497-505. 10.1001/jama.272.19.1497, 7966841.
4. Chalmers GW, Macleod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001, 120:1917-1922. 10.1378/chest.120.6.1917, 11742922.
5. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax 2009, 64(8):728-35. 10.1136/thx.2008.108027, 19638566.
6. Rutgers SR, Postma SD, ten Hacken NHT, Kauffman HF, Mark TW, Koëter GH, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000, 55:12-18. 10.1136/thorax.55.1.12, 1745599, 10607796.
7. Laperre TS, Postma DS, Gosman MME, Snoeck-Stroband JB, ten Hacken NHT, Hiemstra PS, Timens W, Sterk PJ, Mauad T. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2006, 61:115-121. 10.1136/thx.2005.040519, 2104584, 16055612.
8. Louhelainen N, Rytilä P, Haahtela T, Kinnula VL, Djukanovic R. Persistence of oxidant and protease burden in the airways after smoking cessation. BMC Pulm Med 2009, 27(9):25.
9. Bergeron C, Tulic MK, Hamid Q. Tools used measure airway remodellation in research. Eur Respir J 2007, 29:596-604. 10.1183/09031936.00019906, 17329494.
10. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006, 61:259-266. 10.1136/thx.2005.051979, 2080735, 16227332.
11. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004, 56:515-548. 10.1124/pr.56.4.2, 15602009.
12. Burke B. The role of matrix metalloproteinase 7 in innate immunity. Immunobiology 2004, 209(1-2):51-56. 10.1016/j.imbio.2004.04.005, 15481140.
13. Lohi J, Wilson CL, Roby JD, Parks WC. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem 2001, 276:10134-10144. 10.1074/jbc.M001599200, 11121398.
14. Kinnula VL. Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases. Thorax 2005, 60:693-700. 10.1136/thx.2004.037473, 1747473, 16061713.
15. Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005, 99:703-710. 10.1016/j.rmed.2004.10.022, 15878486.
16. Ilumets H, Rytilä P, Demedts I, Brusselle GG, Sovijärvi A, Myllärniemi M, Sorsa T, Kinnula VL. Matrix metalloproteinases -8, -9 and -12 in smokers and patients with Stage 0 COPD. Int J COPD 2007, 2(3):369-379.
17. Demedts IK, Brusselle GG, Bracke KR, Vermaelen KY, Pauwels RA. Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol 2005, 5(3):257-63. 10.1016/j.coph.2004.12.005, 15907912.
18. Djukanovic R, Sterk PJ, Fahy JV, Hargreave HH. Standardised methodology of sputum induction and processing. Eur Respir J 2002, 37(Suppl):1s-2s.
19. Louhelainen N, Myllärniemi M, Rahman I, Kinnula VL. Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: current and future perspectives. Int J Chron Obstruct Pulmon Dis 2008, 3(4):585-603. 2650600, 19281076.
20. [GINA] Global Initiative for Asthma Global strategies for asthma management and prevention. NIH Publication, No 02-3659 2002, National Institutes of Health, National Heart, Lung and Blood Institute. [online], [GINA] Global Initiative for Asthma., http://www.ginasthma.com
21. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
22. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. 2004, World Medical Association., http://www.wma.net/en/30publications/10policies/b3/index.html
23. ATS/ERS Standardization of spirometry. Eur Respir J 2005, 26:319-338. 10.1183/09031936.05.00034805, 16055882, ATS/ERS.
24. Viljanen AA, Halttunen PK, Kreus KE, Viljanen BC. Spirometric studies in non-smoking healthy adults. Scand J Clin Lab Invest 1982, 159:5-20.
25. Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002, 57:967-972. 10.1136/thorax.57.11.967, 1746230, 12403880.
26. Burchfiel CM, Marcus EB, Curb JD, Maclean CJ, Vollmer WM, Johnson LR, Fong KO, Rodriguez BL, Masaki KH, Buist AS. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995, 151:1778-1785.
27. Townsend MC, DuChene AG, Morgan J, Browner WS. Pulmonary function in relation to cigarette smoking and smoking cessation. Prev Med 1991, 20:621-637. 10.1016/0091-7435(91)90059-D, 1758842.
28. Ilumets H, Rytila PH, Sovijärvi AR, Tervahartiala T, Myllärniemi M, Sorsa TA, Kinnula VL. Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation. Scan J Clin Lab Invest 2008, 9:1-6.
29. Lowrey GE, Henderson N, Blakey JD, Corne JM, Johnson SR. MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Respir Med 2008, 102(6):845-51. 10.1016/j.rmed.2008.01.006, 18328682.
30. Yoon HK, Cho HY, Kleeberger SR. Protective role of matrix metalloproteinase-9 in ozone induced airway inflammation. Environ Health Perspect 2007, 115:1557-1563. 10.1289/ehp.10289, 2072825, 18007984.
31. Willemse BWM, ten Hacken NHT, Rutgers B, Lesman-Leegte IGAT, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2004, 26:835-845.
32. Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaier R, Wouters EF. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004, 126:1082-1010.
33. Demedts IK, Morel-Montero A, Lebecque S, Pacheco Y, Cataldo D, Joos GF, Pauwels RA, Brusselle CG. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 2006, 61(3):196-201. 10.1136/thx.2005.042432, 2080750, 16308335.
34. Babusyte A, Stravinskaite K, Jeroch J, Lötvall J, Sakalauskas R, Sitkauskiene B. Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD. Respir Res 2007, 14(8):81.
35. Deshmukh HS, Shacer C, Case LM, Dietsch M, Wesselkamper SC, Hardie WD, Korfhagen TR, Corradi M, Nadel JA, Borchers MT, Leikauf GD. Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production. Am J Respir Cell Mol Biol 2008, 38(4):446-54. 10.1165/rcmb.2006-0339OC, 2274947, 18006877.
36. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, Lewis CE. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 2003, 163:1233-1243. 1868302, 14507633.
37. Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, Parks WC. Matrilysin expression and function in airway epithelium. J Clin Invest 1998, 102(7):1321-31. 10.1172/JCI1516, 508979, 9769324.
38. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005, 100(7):1012-1020. 10.1111/j.1360-0443.2005.01097.x, 15955017.